Overview

Bolt Biotherapeutics develops ISACs (Immune-Stimulating Antibody Conjugates) to treat cancer by activating the patient’s own immune system. Its therapies use a proprietary platform that targets dendritic cells and other myeloid cells to reawaken anti-tumor immunity and create systemic immune memory. They focus on patients who do not respond to traditional checkpoint inhibitors and work with oncologists and cancer treatment centers to advance development and commercialization. The product works as an antibody-based conjugate that stimulates immune cells to recognize and attack tumors, with the aim of providing durable clinical benefits. The company differentiates itself by leveraging dendritic and myeloid cell biology through a dedicated platform to drive sustained immune responses, targeting a class of therapies designed for long-term cancer control. Bolt Biotherapeutics’ goal is to deliver long-lasting, tumor-specific immune memory that improves outcomes for cancer patients.